CLINICAL_TRIALS
trial_result
· 2016-10-07
Clinical Trial Update: Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia [Phase 3]
Summary
A Phase 3 trial evaluating an FDA-approved drug as add-on therapy for schizophrenia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: GlaxoSmithKline | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED